1-500 | 501-665
    Part,  Chapter, Paragraph

  1    I,     2.  3        |               European Union alone, 500 000 girls and women are affected
  2    I,     2.  7        |               Hammarby Sjostad zone, 10,000 flats for 25,000 inhabitants,
  3    I,     2.  7        |               zone, 10,000 flats for 25,000 inhabitants, is an example
  4    I,     2.  7        |          created, to be inhabited by 80,000 people. It will be named
  5    I,     3.  2        |               and migration rate (per 1,000 population), 2005~ ~The
  6   II,     5.  2.  1    |                 accounting for over 741,000 deaths every year (one in
  7   II,     5.  2.  1    |               the EU accounting for 508,000 deaths each year: around
  8   II,     5.  2.  3    |                 accounting for over 741.000 deaths every year: one in
  9   II,     5.  2.  3    |                from 42.7 deaths per 100.000 in France to 327.0 deaths
 10   II,     5.  2.  3    |                 to 327.0 deaths per 100.000 in Latvia, being there almost
 11   II,     5.  2.  3    |                in men 72 deaths per 100.000 in France and 555 in Latvia;
 12   II,     5.  2.  3    |             Latvia; in women 16 per 100.000 in France and 167 in Latvia).~ ~
 13   II,     5.  2.  3    |                 mortality rates per 100.000.~ ~Mortality trends for
 14   II,     5.  2.  3    |                 from 300 to 186 per 100.000), 45% in Central Eastern
 15   II,     5.  2.  3    |                 from 440 to 242 per 100.000), 27% in Eastern Europe
 16   II,     5.  2.  3    |                 from 450 to 326 per 100.000), 37% in Central Europe
 17   II,     5.  2.  3    |                 from 225 to 142 per 100.000), 34% in Southern Europe
 18   II,     5.  2.  3    |                  from 139 to 91 per 100.000) and 27% in Baltic7 countries (
 19   II,     5.  2.  3    |                 from 696 to 505 per 100.000). Similar results can be
 20   II,     5.  2.  3    |        countries (from 73 to 44 per 100.000), 51% in Central Eastern
 21   II,     5.  2.  3    |                  from 157 to 77 per 100.000), 23% in Eastern Europe
 22   II,     5.  2.  3    |                 from 169 to 130 per 100.000), 41% in Northern Europe (
 23   II,     5.  2.  3    |                  from 102 to 61 per 100.000), 36% in Baltic Europe countries (
 24   II,     5.  2.  3    |                 from 231 to 148 per 100.000) and 41% in Southern Europe
 25   II,     5.  2.  3    |        countries (from 40 to 23 per 100.000).~ ~Figure 5.2.1. Age-standardized
 26   II,     5.  2.  3    |                 mortality rates per 100.000. Trends for ischemic heart
 27   II,     5.  2.  3    |                 mortality rates per 100.000. Trends for ischemic heart
 28   II,     5.  2.  3    |          hospital discharge rates (x100.000) from all CVD, IHD,AMI,
 29   II,     5.  2.  3    |               recurrent events) per 100.000 during 10-year registration
 30   II,     5.  2.  3    |                 accounting for over 508.000 deaths each year. Around
 31   II,     5.  2.  3    |                 mortality rates per 100.000 men and women aged 35-74
 32   II,     5.  2.  3    |           varies from 60 deaths per 100.000 in France to 399 deaths
 33   II,     5.  2.  3    |            France to 399 deaths per 100.000 in Romania, being there
 34   II,     5.  2.  3    |           varies from 36 deaths per 100.000 in France to 297 deaths
 35   II,     5.  2.  3    |                  from 133 to 49 per 100.000), 40% in Southern Europe
 36   II,     5.  2.  3    |                  from 136 to 82 per 100.000), 21% in Northern countries (
 37   II,     5.  2.  3    |                  from 110 to 87 per 100.000), 34% in Central Eastern
 38   II,     5.  2.  3    |                 from 273 to 180 per 100.000) and 6% in Baltic Europe
 39   II,     5.  2.  3    |                 from 298 to 279 per 100.000). Mortality increased by
 40   II,     5.  2.  3    |                 from 324 to 357 per 100.000). In 2003, mortality rates
 41   II,     5.  2.  3    |                 mortality rates per 100.000 Cerebrovascular disease (
 42   II,     5.  2.  3    |           Europe (from 89 to 54 per 100.000), 46% in Southern Europe
 43   II,     5.  2.  3    |        countries (from 99 to 54 per 100.000), 21% in Northern countries (
 44   II,     5.  2.  3    |        countries (from 87 to 68 per 100.000), 13% in Baltic Europe countries (
 45   II,     5.  2.  3    |                 from 218 to 189 per 100.000) and 37% in Central Eastern
 46   II,     5.  2.  3    |                 from 193 to 121 per 100.000). Mortality rates increased
 47   II,     5.  2.  3    |                 from 203 to 246 per 100.000). In 2003, mortality rates
 48   II,     5.  2.  3    |                 mortality rates per 100.000 Cerebrovascular disease (
 49   II,     5.  2.  3    |            fatal and non fatal) per 100.000 mean of the last 3 years
 50   II,     5.  2.  6    |             prospective studies with 55,000 vascular deaths. Lancet
 51   II,     5.  3.  1    |                new cancer cases per 100,000 population at risk;~ ~-
 52   II,     5.  3.  1    |               deaths for cancer per 100,000 population at risk;~ ~-
 53   II,     5.  3.  5    |             performance. In 2006, 3,200,000 new cases and 1,700,000
 54   II,     5.  3.  5    |                 000 new cases and 1,700,000 deaths were estimated for
 55   II,     5.  3.  5    |              men (599 new cases per 100,000) and in Denmark for women (
 56   II,     5.  3.  5    |            women (414 new cases per 100,000). Maximum mortality rates (
 57   II,     5.  3.  5    |                 men (364 deaths per 100,000) and in Denmark for women (
 58   II,     5.  3.  5    |               women (196 deaths per 100,000). The highest incidence
 59   II,     5.  3.  5    |              men (482 new cases per 100,000, Figure 5.3.2a) and in Northern
 60   II,     5.  3.  5    |            women (351 new cases per 100,000, Figure 5.3.2b), while the
 61   II,     5.  3.  5    |                 men (287 deaths per 100,000, Figure 5.3.4a) and again
 62   II,     5.  3.  5    |               women (155 deaths per 100,000, Figure 5.3.4b).~Figures
 63   II,     5.  3.  5    |                 In 2006 Europe saw, 160,000 new cases and 118,000 deaths
 64   II,     5.  3.  5    |               160,000 new cases and 118,000 deaths estimated for stomach
 65   II,     5.  3.  5    |               men (37 new cases per 100,000) and in Lithuania for women (
 66   II,     5.  3.  5    |             women (18 new cases per 100,000); while maximum levels of
 67   II,     5.  3.  5    |              for men (29 deaths per 100,000) and in Estonia for women (
 68   II,     5.  3.  5    |                women (12 deaths per 100,000). Incidence and mortality
 69   II,     5.  3.  5    |            ICD-9 153, 154)~In 2006, 413,000 new cases and 207,000 deaths
 70   II,     5.  3.  5    |               413,000 new cases and 207,000 deaths were estimated for
 71   II,     5.  3.  5    |              men (106 new cases per 100,000) and Switzerland for women (
 72   II,     5.  3.  5    |             women (56 new cases per 100,000). Finland had lower male
 73   II,     5.  3.  5    |                and 41 new cases per 100,000 in women). Figures 5.3.11
 74   II,     5.  3.  5    |                  over 40 deaths per 100,000) and for women (over 24
 75   II,     5.  3.  5    |                  over 24 deaths per 100,000).~Colorectal cancer incidence
 76   II,     5.  3.  5    |                in Europe there were 386,000 new cases and 335,000 estimated
 77   II,     5.  3.  5    |               386,000 new cases and 335,000 estimated deaths (Ferlay
 78   II,     5.  3.  5    |            cases and 110 deaths per 100,000) against Sweden with minimum
 79   II,     5.  3.  5    |             cases and 29 deaths per 100,000). Sweden had a lower male
 80   II,     5.  3.  5    |                 vs 41 new cases per 100,000). Eastern Europe had maximum
 81   II,     5.  3.  5    |             cases and 85 deaths per 100,000). While Northern Europe
 82   II,     5.  3.  5    |             cases and 27 deaths per 100,000 in 2006).~Most European
 83   II,     5.  3.  5    |             women with an estimated 430,000 new cases and 132,000 deaths
 84   II,     5.  3.  5    |               430,000 new cases and 132,000 deaths in 2006 for the entire
 85   II,     5.  3.  5    |          Belgium (138 new cases per 100,000). Breast cancer incidence
 86   II,     5.  3.  5    |           Iceland) to 34 deaths per 100,000 (in Denmark). Mortality
 87   II,     5.  3.  5    |                 estimates were about 60,000 new cases and 30,000 deaths
 88   II,     5.  3.  5    |                 60,000 new cases and 30,000 deaths in 2002 for the entire
 89   II,     5.  3.  5    |                 ICD-9 185)~In 2006, 346,000 new cases and 87,000 deaths
 90   II,     5.  3.  5    |                346,000 new cases and 87,000 deaths were estimated for
 91   II,     5.  4.  2    |              Type 1 diabetes by age/100,000 population 014 years~12~
 92   II,     5.  4.  2    |                patients with diabetes/1,000,000 general population~11~
 93   II,     5.  4.  2    |            patients with diabetes/1,000,000 general population~11~HIS/
 94   II,     5.  4.  2    |               patients with diabetes /1,000,000 general population~11~
 95   II,     5.  4.  2    |           patients with diabetes /1,000,000 general population~11~HIS/
 96   II,     5.  4.  2    |             death diabetes mellitus/100,000 general population~12~National
 97   II,     5.  4.  2    |         population from all causes /100,000 general population, adjusted
 98   II,     5.  4.  2    |            children in one year per 100.000 children.~Prevalence of
 99   II,     5.  4.  2    |            replacement therapy) per 100,000 individuals in the diabetic
100   II,     5.  4.  2    |                 transplantation per 100.000 diabetic population is defined
101   II,     5.  4.  2    |                 transplantation per 100,000 individuals in the diabetic
102   II,     5.  4.  2    |             death diabetes mellitus/100,000 general population. Despite
103   II,     5.  4.  2    |               in diabetic patients /100,000 general population~9~Annual
104   II,     5.  4.  2    |               in diabetic patients /100,000 general population~10~Annual
105   II,     5.  4.  2    |                in diabetic patients/100,000 general population~10~ ~
106   II,     5.  4.  2    |       amputations (above ankle) per 100,000 individuals in the diabetic
107   II,     5.  4.  2    |          ischemic and bleeding) per 100,000 individuals in the diabetic
108   II,     5.  4.  2    |           myocardial infarction per 100,000 individuals in the diabetic
109   II,     5.  4.  3    |                  Finland) cases per 100,000 per year. The median value
110   II,     5.  4.  3    |               to 149 (Scotland) per 100,000, with a median of 79 (Denmark).
111   II,     5.  4.  3    |                 transplantation per 100.000 diabetic population. Across
112   II,     5.  4.  3    |                 median of 304 every 100,000 diabetics, corresponding
113   II,     5.  4.  3    |              and 199 (Portugal) per 100,000 in 10 countries delivering
114   II,     5.  4.  3    |              The median value is 31/100,000, corresponding to France.
115   II,     5.  4.  3    |                2007 a total of over 300,000 deaths are attributable
116   II,     5.  4.  3    |                  to 574 (Spain) per 100,000 diabetes patients, with
117   II,     5.  4.  3    |                 a median of 669 per 100,000. There is a clear influence
118   II,     5.  4.  4    |                 town of Europe with 100 000 inhabitants would loose
119   II,     5.  5.Int    |            varies between 3 and 6 per 1.000 inhabitants. Data, though
120   II,     5.  5.  1    |                 Across the EU, about 59 000 citizens, 45 000 men and
121   II,     5.  5.  1    |               about 59 000 citizens, 45 000 men and 14 000 women committed
122   II,     5.  5.  1    |             citizens, 45 000 men and 14 000 women committed suicide
123   II,     5.  5.  1    |              road accidents of about 50 000 deaths (Eurostat). The EU
124   II,     5.  5.  1    |              disorders as total per 100 000 population for newly diagnosed
125   II,     5.  5.  1    |           self-inflicted injury per 100 000 population. Age standardisation
126   II,     5.  5.  1    |           intentional self-harm per 100 000 whole population (standardized
127   II,     5.  5.  1    |             inflicted accidents per 100 000 people by country and gender
128   II,     5.  5.  1    |            inflicted accidents (per 100 000 people) by gender in Europe~ ~
129   II,     5.  5.  1    |            inflicted accidents (per 100 000) in Europe.~ ~The changes
130   II,     5.  5.  1    |                global level, 70 per 100 000 and Lithuanian women have
131   II,     5.  5.  1    |               the world with 14 per 100 000 (WHO statistics).~ ~
132   II,     5.  5.  3    |              bulimia affects 30 per 100.000 females, whereby the incidence
133   II,     5.  5.  3    |          incidence rate of 81,1 per 100.000 (Hoek and van Hoeken, 2003).~
134   II,     5.  5.  3    |                 of Eating Disorder 00:0 000-000 2008-DOI 10.1002/eat.~
135   II,     5.  5.  3    |                Eating Disorder 00:0 000-000 2008-DOI 10.1002/eat.~Misra
136   II,     5.  5.  3    |           lifetime is about seven per 1 000 people. The latest available
137   II,     5.  5.  3    |                 prevalence of 4.6 per 1 000, 3.3 for period prevalence,
138   II,     5.  5.  3    |               between 16 and 42 per 100 000 population experience a
139   II,     5.  5.  3    |                 F20-death rates per 100 000 inhabitants would allow
140   II,     5.  5.  3    |           Considering in-patients per 1,000 populations (see Figure
141   II,     5.  5.  3    |    psychologists from 0.1 to 96 per 100 000 population (WHO, 2005c).
142   II,     5.  5.  3    |           eight-year-olds (65.88 per 10,000) were identified as having
143   II,     5.  5.  3    |            finding of 6.6 and 6.7 per 1,000 eight-year-olds translates
144   II,     5.  5.  3    |           Disorders (ASD) from 4 per 10,000 to 66 per 10000 children
145   II,     5.  5.  3    |            ranges from 44 to 73 per 100,000, while the incidence of
146   II,     5.  5.  3    |            ranges from 24 to 57 per 100,000 (Forsgren et al, 2005; Olafsson
147   II,     5.  5.  3    |                 4.2. Incidence (per 100,000) of epilepsy in Europe,
148   II,     5.  5.  3    |                  incidence 23.5 per 100,000 per year). Undetermined
149   II,     5.  5.  3    |            occurred in 15% (8.7 per 100,000 per year), cryptogenic localization-related
150   II,     5.  5.  3    |            epilepsy in 16% (8.8 per 100,000 per year), symptomatic localization-related
151   II,     5.  5.  3    |            epilepsy in 15% (8.4 per 100,000 per year), and idiopathic
152   II,     5.  5.  3    |             epilepsy in 6% (3.4 per 100,000 per year). In Bordeaux,
153   II,     5.  5.  3    |               The rate was 15.3 per 100,000 for localization-related
154   II,     5.  5.  3    |          symptomatic 13.6), 6.7 per 100,000 for generalized epilepsies (
155   II,     5.  5.  3    |        symptomatic 1.1) and 1.9 per 100,000 for undetermined epilepsies (
156   II,     5.  5.  3    |            ranges from 3.2 to 7.8 per 1,000 (Table 5.5.3.4.3). The prevalence
157   II,     5.  5.  3    |                 Prevalence ratio (per 1,000)~Reference(s), year~ ~Denmark ~
158   II,     5.  5.  3    |                epilepsies was 1.2 per 1,000, while that of cryptogenic
159   II,     5.  5.  3    |                epilepsies was 1.0 per 1,000. In another study of childhood
160   II,     5.  5.  3    |           syndromic category (1.5 per 1,000) followed by generalized
161   II,     5.  5.  3    |       generalized epilepsies (1.3 per 1,000) and undetermined epilepsies (
162   II,     5.  5.  3    |      undetermined epilepsies (0.6 per 1,000). Localization-related epilepsies
163   II,     5.  5.  3    |              ranges from 1 to 8 per 100,000 population per year, but
164   II,     5.  5.  3    |          mortality rates at 1-2 per 100,000 (Massey et al, 1985).~In
165   II,     5.  5.  3    |            mortality rate of 6.23 per 1,000 person-years was reported (
166   II,     5.  5.  3    |               SUDEP ranges from 1 per 1,000 in prevalence studies (O’
167   II,     5.  5.  3    |              Sander, 1997) to 3.5 per 1,000 in incidence studies (Nashef
168   II,     5.  5.  3    |             SUDEP was 2.5 vs. 6.3 per 1,000 (Nilsson et al, 2003). There
169   II,     5.  5.  3    |             cohort study of more than 9,000 patients once hospitalized
170   II,     5.  5.  3    |        population-based studies (ie, 50 000 pop. and over, registry-based
171   II,     5.  5.  3    |                5.2. Prevalence (per 100 000) of Multiple Sclerosis in
172   II,     5.  5.  3    |                5.3. Prevalence (per 100 000) of Multiple Sclerosis in
173   II,     5.  5.  3    |                 5.4. Incidence (per 100 000/year) of Multiple Sclerosis
174   II,     5.  5.  3    |       significantly from 3 to 6 per 100 000 per year in the western
175   II,     5.  5.  3    |                 in France is 65 per 100 000 (Vukusic et al, 2007), and
176   II,     5.  5.  3    |         Prevalence of 39 and 21 per 100 000 has been reported for Bulgaria
177   II,     5.  5.  3    |               approx. 20 to 190 per 100 000. Mean rates are higher in
178   II,     5.  5.  3    |              between 11 and 282 per 100 000 in women and between 10
179   II,     5.  5.  3    |              between 10 and 123 per 100 000 in men, with female:male
180   II,     5.  5.  3    |               estimated to be 4 per 100 000, with peaks registered registered
181   II,     5.  5.  3    |                 from 0.6 to 1.0 per 100 000 as reported by WHO for 2002 (
182   II,     5.  5.  3    |                 rates up to 3.6 per 100 000 are reported in the scientific
183   II,     5.  5.  3    |                 5.7. Mortality (per 100 000) of MS patients in selected
184   II,     5.  5.  3    |                 for MS in Europe is 307 000 years and varies according
185   II,     5.  5.  3    |             mortality strata, being 157 000 in the very-low-child/very-low-adult
186   II,     5.  5.  3    |              very-low-adult stratum, 63 000 in the low-child/low-adult
187   II,     5.  5.  3    |              low-child/low-adult and 87 000 in the low-child/high-adult
188   II,     5.  5.  3    |               in Europe ranges from €10 000 to €54 000, with a mean
189   II,     5.  5.  3    |              ranges from €10 000 to €54 000, with a mean of €31 000.
190   II,     5.  5.  3    |                 000, with a mean of €31 000. Direct costs, excluding
191   II,     5.  5.  3    |         prevalence (MSA:1.86 to 4.9/100.000, PSP: 2.5 to 7.5/100.000;
192   II,     5.  5.  3    |                000, PSP: 2.5 to 7.5/100.000; CGD: 4.0/100.000, respectively (
193   II,     5.  5.  3    |                 5/100.000; CGD: 4.0/100.000, respectively (Nath et al,
194   II,     5.  5.  3    |              age groups (>85y; 2205/100.000), however, approximately
195   II,     5.  5.  3    |             estimates varied from 5/100,000 to 346/100,000. The latter
196   II,     5.  5.  3    |               from 5/100,000 to 346/100,000. The latter estimate is
197   II,     5.  5.  3    |             considerably, from 65.6/100,000 in Sardinia (Rosati et al,
198   II,     5.  5.  3    |                 al, 1980) to 12,500/100,000 for institutionalised patients
199   II,     5.  5.  3    |            approximately 120 to 257/100,000 and 11 to 19/100,000 per
200   II,     5.  5.  3    |                100,000 and 11 to 19/100,000 per year, respectively.
201   II,     5.  5.  3    |              higher: 1,280 to 1,500/100,000 and 346/100,000, respectively.
202   II,     5.  5.  3    |                 500/100,000 and 346/100,000, respectively. The large
203   II,     5.  5.  3    |               rates (65.6 to 12,500/100,000) may be the consequence
204   II,     5.  5.  3    |                prevalence of 12,500/100,000 was obtained from a study
205   II,     5.  5.  3    |             Europe range from 5 per 100,000 to 26 per 100,000, according
206   II,     5.  5.  3    |               per 100,000 to 26 per 100,000, according to the identified
207   II,     5.  5.  3    |           incidence rate of 326 per 100,000 for people aged 65-84 (Baldereschi
208   II,     5.  5.  3    |             from €2,500 (Estonia) – €13,000 (Switzerland) with an average
209   II,     5.  6.  3    |                and 140 procedures / 100,000 (Merx et al, 2003). The
210   II,     5.  6.  3    |                 range from 413 per 100,000 for adult males and 13-36
211   II,     5.  6.  3    |                 males and 13-36 per 100,000 for adult females. Estimates
212   II,     5.  6.  3    |                age, with rates of 2/100,000 person-years in women aged
213   II,     5.  6.  3    |             under 35,rising to 3032/100,000 person-years in women 85
214   II,     5.  6.  3    |           incidences of 9 and 37 per 10 000 men and women respectively,
215   II,     5.  7.  1    |            entails a cost excess of $26.000 per case per year in the
216   II,     5.  8.  1    |    under-treated.~ ~ ~Approximately 200 000-300 000 people die every
217   II,     5.  8.  1    |               Approximately 200 000-300 000 people die every year in
218   II,     5.  8.  3    |        geographical areas with nearly 5 000 patients, has estimated
219   II,     5.  8.  3    |                   from 1.9 to 2.9 per 1 000) in males and by 90% in
220   II,     5.  8.  3    |          females (from 1.0 to 2.9 per 1 000) from 2000 to 2025 (Hoogendoorn
221   II,     5.  8.  3    |          disease severity, data from 18 000 young adults (2044 years)
222   II,     5.  8.  3    |        symptomatic.~ ~Prevalence (per 1 000 in Dutch population) reported
223   II,     5.  8.  3    |              300 lost work days per 100 000 population are due to this
224   II,     5.  8.  3    |               300 € in Spain and 150, 3 000, 3 900 in Italy, respectively
225   II,     5.  9.  2    |           stages including more than 18,000 individuals aged 20 to 44
226   II,     5.  9.  2    |      prospective survey of more than 10,000 young adults begun in 1998.~ ~
227   II,     5.  9.  3    |                 are estimated to be 250,000 per year worldwide. EU mortality
228   II,     5.  9.  3    |       Standardized Death Rates (per 100,000 people) in all EU Countries
229   II,     5.  9.  3    |                people suggest that: 665.000 people with wheezing are
230   II,     5. 11.  3    |               cases of melanoma per 100,000. Many cancer registries
231   II,     5. 11.  3    |             skinned population (per 100 000).~ ~ ~There is little information
232   II,     5. 11.  3    |            incidence rate of 88 per 100 000 for BCC, of 29 per 100 000
233   II,     5. 11.  3    |              000 for BCC, of 29 per 100 000 for SCC and 14 per 100 000
234   II,     5. 11.  3    |              000 for SCC and 14 per 100 000 for melanoma (de Rijke et
235   II,     5. 11.  3    |             that in 2000 there were 132 000 cases of melanoma diagnosed
236   II,     5. 11.  3    |             diagnosed world-wide and 37 000 deaths caused by melanoma.
237   II,     5. 11.  3    |              that in 2000 there were 35 000 cases of melanoma diagnosed
238   II,     5. 11.  3    |            high-resource countries (104 000 cases and 25 000 deaths)
239   II,     5. 11.  3    |         countries (104 000 cases and 25 000 deaths) and low- and medium-resource
240   II,     5. 11.  3    |          countries (28 500 cases and 12 000 deaths) (Ferlay et al, 2001).
241   II,     5. 12.  1    |                 rates (around 30-40/100,000 men and 10-16/100,000 women)
242   II,     5. 12.  1    |               100,000 men and 10-16/100,000 women) in Europe were observed
243   II,     5. 12.  1    |               lowest ones (below 10/100,000 men and 5/100,000 women)
244   II,     5. 12.  1    |                10/100,000 men and 5/100,000 women) were registered in
245   II,     5. 12.  1    |              reaching rates over 58/100,000 men and 22/100,000 women
246   II,     5. 12.  1    |               58/100,000 men and 22/100,000 women in Hungary in 1990 (
247   II,     5. 12.  2    |          Age-standardized rates per 100,000 population, at all ages
248   II,     5. 12.  3    |            rates from cirrhosis per 100,000 men at all ages and at 35-
249   II,     5. 12.  3    |                 i.e. Portugal (38.7/100,000), Italy (35.0), France (
250   II,     5. 12.  3    |              England and Wales (3.6/100,000), Ireland (3.4), Norway
251   II,     5. 12.  3    |             rates between 12 and 15/100,000, and Portugal of around
252   II,     5. 12.  3    |               Portugal of around 18/100,000. Similar declines were observed
253   II,     5. 12.  3    |             rates were around 10-13/100,000 men in the early 1980s and
254   II,     5. 12.  3    |            early 1980s and around 5/100,000 in 2000-02. Consequently,
255   II,     5. 12.  3    |             rates remained around 5/100,000 men throughout all the calendar
256   II,     5. 12.  3    |                 in 1980-82 to 18-20/100,000 in 2000-02, and even smaller
257   II,     5. 12.  3    |               in 2000-02 were 31-35/100,000 men. Eight European countries
258   II,     5. 12.  3    |               11.3 in 1980-82 to 15/100,000 in 2000-2002, Finland from
259   II,     5. 12.  3    |                rates reaching 172.2/100,000 men in Hungary and 106.1
260   II,     5. 12.  3    |          middle-aged men (around 75/100,000).~Mortality rates from cirrhosis
261   II,     5. 12.  3    |                in 2000-02 were 22.6/100,000 in Romania, followed by
262   II,     5. 12.  3    |                lowest ones, below 2/100,000, were in Greece and Malta.
263   II,     5. 12.  3    |                 for women were 53.9/100,000 in Hungary and 44.3 in Romania.
264   II,     5. 12.  3    |             cirrhosis (around 24-30/100,000).~ ~Table 5.12.2. Age-adjusted (
265   II,     5. 12.  3    |            rates from cirrhosis per 100,000 women at all ages and at
266   II,     5. 14.  2    |               number and rates (per 100,000 population) of active dentists,
267   II,     5. 14.  2    |              clinical providers per 100,000 population.~Denominator:
268   II,     5. 15.  1    |              threshold as around 1 in 2,000 (precisely 1 in 2,000 in
269   II,     5. 15.  1    |                 2,000 (precisely 1 in 2,000 in Europe).~For the organisation
270   II,     5. 15.  1    |               is probably around 1 in 5 000 or 1 in 10 000~( ht ).~From
271   II,     5. 15.  1    |            around 1 in 5 000 or 1 in 10 000~( ht ).~From a public health
272   II,     5. 15.  1    |               is probably around 1 in 1 000.~ ~Therefore, although it
273   II,     5. 15.  1    |                that there are between 5 000 and 8 000 distinct rare diseases,
274   II,     5. 15.  1    |                 are between 5 000 and 8 000 distinct rare diseases,
275   II,     5. 15.  2    |               contains a list of over 5 000 RD and provides textual
276   II,     5. 15.  3    |              very low numbers. Of the 5,000 RD listed in Orphanet, only
277   II,     5. 15.  3    |               ranging from 5 to 1 in 10 000 and 233 RD have a prevalence
278   II,     5. 15.  3    |                 ranging between 1 in 10 000 and 1 in 100 000. Another
279   II,     5. 15.  3    |                1 in 10 000 and 1 in 100 000. Another 1 000 RD have probably
280   II,     5. 15.  3    |                 1 in 100 000. Another 1 000 RD have probably a prevalence
281   II,     5. 15.  3    |              records (HDRs), is 5 per 1 000 inhabitants with a confidence
282   II,     6.  3.  2    |              year can be estimated at 3 000 000, and approximately 50
283   II,     6.  3.  2    |               can be estimated at 3 000 000, and approximately 50 000
284   II,     6.  3.  2    |               000, and approximately 50 000 deaths occur every year
285   II,     6.  3.  2    |                 of the infection. Of 87 000 patients staying more than
286   II,     6.  3.  3    |                it is estimated that 720 000 people were living with
287   II,     6.  3.  3    |               of 2005 and that about 15 000 individuals are becoming
288   II,     6.  3.  3    |             Iceland with 552.45 per 100 000, followed by Denmark with
289   II,     6.  3.  3    |             Denmark with 441.29 per 100 000. Available data show that
290   II,     6.  3.  3    |                 up to 200 cases per 100 000 per year in 1995, to below
291   II,     6.  3.  3    |               1995, to below 40 per 100 000 per year in 2004. In the
292   II,     6.  3.  3    |                in the UK (33.98 per 100 000), followed by Latvia (30.
293   II,     6.  3.  3    |                by Latvia (30.09 per 100 000) and the lowest in Luxembourg (
294   II,     6.  3.  3    |                Luxembourg (0.22 per 100 000), followed by Spain and
295   II,     6.  3.  3    |                  both with 0.42 per 100 000). However, different surveillance
296   II,     6.  3.  3    |                under 3.5 to 2.2 per 100 000 per year in 2000, but has
297   II,     6.  3.  3    |               then reaching 3.1 per 100 000 per year in 2004, mainly
298   II,     6.  3.  3    |            1990s (over 60 cases per 100 000 per year in 1995), a sharp
299   II,     6.  3.  3    |         remained below 10 cases per 100 000 per year, with an overall
300   II,     6.  3.  3    |                in Latvia (19.21 per 100 000), Lithuania (8.61 per 100
301   II,     6.  3.  3    |                 Lithuania (8.61 per 100 000) and Estonia (8.24 per 100
302   II,     6.  3.  3    |               and Estonia (8.24 per 100 000), with the 2544 age group
303   II,     6.  3.  3    |              sex partners.~ ~Almost 180 000 cases of Hepatitis B were
304   II,     6.  3.  3    |                6.6 to 2.6 cases per 100 000 per year over the period.
305   II,     6.  3.  3    |               by Iceland (11.24 per 100 000), followed by Latvia (7.
306   II,     6.  3.  3    |                 by Latvia (7.37 per 100 000). Incidence was higher in
307   II,     6.  3.  3    |               steadily from 7.0 per 100 000 per year in 2001, to 7.9
308   II,     6.  3.  3    |                 in 2001, to 7.9 per 100 000 per year in 2004, but this
309   II,     6.  3.  3    |         artefact. In 2005, more than 29 000 hepatitis C cases were reported
310   II,     6.  3.  3    |                 incidence rates per 100 000 per year were reported by
311   II,     6.  3.  4    |               remained below 20 per 100 000 per year since 2001 in all
312   II,     6.  3.  4    |                 6.A1.1 TB cases per 100,000 selected countries and EU
313   II,     6.  3.  4    |              overall rate of 13 per 100 000 per year, with a countrywide
314   II,     6.  3.  4    |                Kingdom) had more than 5 000 cases each, accounting for
315   II,     6.  3.  4    |          notification rate (135 per 100 000 per year in 2005) and will
316   II,     6.  3.  4    |            stable at around one per 100 000 per year. In 2005, a total
317   II,     6.  3.  4    |               incidence of 3.36 per 100 000 per year was seen in Spain,
318   II,     6.  3.  4    |               Iceland with 2.38 per 100 000 per year. In 2005, 746 cases
319   II,     6.  3.  5    |              five and six cases per 100 000 per year, but this is a
320   II,     6.  3.  5    |               one and two cases per 100 000 per year. Good vaccines
321   II,     6.  3.  5    |                infections (5.83 per 100 000 per year) were reported
322   II,     6.  3.  5    |        countries. Sweden (15.76 per 100 000) followed by Belgium (15.
323   II,     6.  3.  5    |               by Belgium (15.45 per 100 000) reported the highest incidence
324   II,     6.  3.  5    |                 age group (15.3 per 100 000), followed by the under-4
325   II,     6.  3.  5    |                 age group (14.1 per 100 000), while the incidence rate
326   II,     6.  3.  5    |            incidence varied below 2/100 000 per year with stable trends
327   II,     6.  3.  5    |              Ireland (with 4.94 per 100 000) and Malta (2.73 per 100
328   II,     6.  3.  5    |                 and Malta (2.73 per 100 000) reported the highest incidence
329   II,     6.  3.  5    |                 rate, with 1.48 per 100 000, followed by Sweden (1.31
330   II,     6.  3.  5    |                 by Sweden (1.31 per 100 000). Hib vaccination is now
331   II,     6.  3.  5    |              Netherlands (40.17 per 100 000), with Norway reporting
332   II,     6.  3.  5    |                 a rate of 19.10 per 100 000. By contrast, the overall
333   II,     6.  3.  5    |                 the EU was 4.10 per 100 000 per year. Thus pertussis,
334   II,     6.  3.  5    |              peaked in 1995 (15 per 100 000 per year) with a second
335   II,     6.  3.  5    |                peak in 2000 (11 per 100 000 per year). In Estonia and
336   II,     6.  3.  5    |               incidence of 0.87 per 100 000.~ ~Tetanus~ ~Tetanus is
337   II,     6.  3.  5    |                always below 0.2 per 100 000 per year in the EU15 states,
338   II,     6.  3.  5    |                 were below 0.35 per 100 000 per year, except for Slovenia
339   II,     6.  3.  5    |           incidence was at 0.45 per 100 000 per year in 2000 (nine cases)
340   II,     6.  3.  5    |              for Malta with 0.5 per 100 000 per year in 2002 (two cases).
341   II,     6.  3.  5    |             were in Malta (0.25 per 100 000), followed by Italy (0.11
342   II,     6.  3.  5    |         followed by Italy (0.11 per 100 000).~ ~
343   II,     6.  3.  5    |            years from almost 35 per 100 000 per year before 1997 to
344   II,     6.  3.  5    |                 to less than 10 per 100 000 per year after 1998 (Figure
345   II,     6.  3.  5    |             between five and 42 per 100 000 per year. In the other countries,
346   II,     6.  3.  5    |              between one and 10 per 100 000 per year since 2000.~ ~In
347   II,     6.  3.  5    |                 the EU was 0.28 per 100 000 per year and the highest
348   II,     6.  3.  5    |               the highest rates per 100 000 were reported by Ireland (
349   II,     6.  3.  5    |          incidence rate below one per 1 000 000 per year during the
350   II,     6.  3.  5    |                rate below one per 1 000 000 per year during the past
351   II,     6.  3.  5    |                 77.24 and 28.95 per 100 000, respectively). In those
352   II,     6.  3.  5    |             countries was 17.65 per 100 000 per year.~ ~Rubella~ ~Rubella
353   II,     6.  3.  5    |              incidence was 0.51 per 100 000 per year, with Lithuania (
354   II,     6.  3.  5    |                 Lithuania (3.44 per 100 000) and the Netherlands (2.
355   II,     6.  3.  5    |               Netherlands (2.23 per 100 000) reporting the highest rates.
356   II,     6.  3.  6    |                increasing trend from 85 000 cases in 1995, to 180 000–
357   II,     6.  3.  6    |               000 cases in 1995, to 180 000190 000 more recently, though
358   II,     6.  3.  6    |                 in 1995, to 180 000–190 000 more recently, though this
359   II,     6.  3.  6    |                  In 2005, more than 200 000 cases were reported, with
360   II,     6.  3.  6    |             Czech Republic (296 per 100 000), followed by the UK (87.
361   II,     6.  3.  6    |                by the UK (87.95 per 100 000). Campylobacteriosis is
362   II,     6.  3.  6    |             Czech Republic (322 per 100 000), followed by Slovakia (
363   II,     6.  3.  6    |                Slovakia (223.67 per 100 000). The highest incidence
364   II,     6.  3.  6    |               Norway, with 0.87 per 100 000, reported the highest incidence
365   II,     6.  3.  6    |                 by the UK (0.79 per 100 000).~ ~Shigellosis~ ~Shigellosis
366   II,     6.  3.  6    |         incidence rate was 1.82 per 100 000, with the highest incidence
367   II,     6.  3.  6    |              five year-old (3.5 per 100 000), representing 10% of all
368   II,     6.  3.  6    |                Lithuania (13.43 per 100 000 total population), followed
369   II,     6.  3.  6    |               by Slovakia (9.51 per 100 000) reported the highest national
370   II,     6.  3.  6    |           Czech Republic (16.72 per 100 000) followed by Sweden (4.27
371   II,     6.  3.  6    |                 by Sweden (4.27 per 100 000) reported the highest incidence.
372   II,     6.  3.  6    |                Lithuania (14.63 per 100 000) followed by Finland (12.
373   II,     6.  3.  6    |                by Finland (12.2 per 100 000) reporting the highest incidence
374   II,     6.  3.  6    |                 the EU was 2.23 per 100 000 per year, with children
375   II,     6.  3.  6    |                 incidence (30.4 per 100 000 per year).~ ~Listeriosis~ ~
376   II,     6.  3.  6    |         incidence in 2004 (0.28 per 100 000 per year) was similar to
377   II,     6.  3.  6    |             2005. Denmark (0.85 per 100 000), followed by Finland (0.
378   II,     6.  3.  6    |                by Finland (0.69 per 100 000) reported the highest incidence
379   II,     6.  3.  6    |                 from 1999 (just under 4 000 cases (0.87 per 100 000))
380   II,     6.  3.  6    |                 000 cases (0.87 per 100 000)) to 2004 (1 743 cases (
381   II,     6.  3.  6    |                 743 cases (0.38 per 100 000)). Twenty-six countries
382   II,     6.  3.  6    |               incidence of 0.31 per 100 000. Portugal (1.40 per 100
383   II,     6.  3.  6    |                  Portugal (1.40 per 100 000), followed by Ireland (1.
384   II,     6.  3.  6    |                by Ireland (1.29 per 100 000) reported the highest incidence
385   II,     6.  3.  6    |                 incidence (0.15 per 100 000).~ ~Cholera~ ~Cholera is
386   II,     6.  3.  6    |                 reported ( 0.01 per 100 000 per year). In 2005, 34 cases
387   II,     6.  3.  6    |                is available. Almost 210 000 cases have been reported
388   II,     6.  3.  6    |                  Slovakia (9.81 per 100 000) and Latvia (6.29 per 100
389   II,     6.  3.  6    |                and Latvia (6.29 per 100 000) are the only countries
390   II,     6.  3.  6    |               of more than five per 100 000 per year. The highest incidence
391   II,     6.  3.  6    |          observed in 1995 (1.68 per 100 000 per year), and has shown
392   II,     6.  3.  6    |                 Lithuania (6.86 per 100 000), followed by Slovakia (
393   II,     6.  3.  6    |               by Slovakia (4.85 per 100 000) reporting the highest incidence.
394   II,     6.  3.  6    |                  Estonia (24.28 per 100 000), followed by Iceland (14.
395   II,     6.  3.  6    |               by Iceland (14.65 per 100 000) reported the highest incidence
396   II,     6.  3.  6    |               scanty. In 2005, almost 8 000 cases were reported by 16
397   II,     6.  3.  6    |             with Ireland (13.75 per 100 000) and the UK (9.26 per 100
398   II,     6.  3.  6    |                and the UK (9.26 per 100 000) reporting the highest incidence
399   II,     6.  3.  6    |                 Lithuania (0.44 per 100 000), followed by Slovenia (
400   II,     6.  3.  6    |               by Slovenia (0.30 per 100 000), reported the highest incidence
401   II,     6.  3.  6    |         countries. Latvia (2.12 per 100 000), followed by Lithuania (
402   II,     6.  3.  6    |                 Lithuania (0.35 per 100 000) reported the highest incidence
403   II,     6.  3.  7    |         countries. Sweden (2.73 per 100 000), followed by Hungary (0.
404   II,     6.  3.  7    |                by Hungary (0.86 per 100 000) reported the highest incidence
405   II,     6.  3.  7    |                 2 and 0.5 cases per 100 000. In 2005, 958 cases were
406   II,     6.  3.  7    |           incidence rates (0.49 per 100 000 and 0.48 per 100 000, respectively).
407   II,     6.  3.  7    |                100 000 and 0.48 per 100 000, respectively). This is
408   II,     6.  3.  7    |                 1 to 0.22 cases per 100 000. The lowest number of cases
409   II,     6.  3.  7    |              with Estonia (0.82 per 100 000) followed by France (0.77
410   II,     6.  3.  7    |                 by France (0.77 per 100 000) reporting the highest incidence.~ ~
411   II,     6.  3.  7    |               from 1.45 to 2.27 per 100 000 per year, with a steady
412   II,     7.  1        |                 each year and about 250,000 citizens of the European
413   II,     7.  3.  1    |            population of Italy:~ ~- 252 000 Fatal Injuries~- 7 000 000
414   II,     7.  3.  1    |              252 000 Fatal Injuries~- 7 000 000 Hospital Admissions~-
415   II,     7.  3.  1    |              000 Fatal Injuries~- 7 000 000 Hospital Admissions~- 34
416   II,     7.  3.  1    |            Hospital Admissions~- 34 200 000 Hospital Outpatients~- 18
417   II,     7.  3.  1    |           Hospital Outpatients~- 18 300 000 Other medical Treatment~ ~·
418   II,     7.  3.  2    |               estimated that almost 100 000 lives could be saved each
419   II,     7.  3.  2    |                72 injury deaths per 100 000 males) than it is for females (
420   II,     7.  3.  2    |                 for females (35 per 100 000 females). As a result, 66%
421   II,     7.  3.  2    |                3. Injury deaths per 100 000 by sex and age group, EU27~ ~
422   II,     7.  3.  3    |                 7 million, more than 19,000 people each day and nearly
423   II,     7.  3.  3    |                 due to injuries per 100 000 inhabitants in the EU27
424   II,     7.  3.  4    |                a daily basis. Almost 50 000 road fatalities (definition
425   II,     7.  3.  4    |               EU27 range from 4 per 100 000 inhabitants in Malta to
426   II,     7.  3.  4    |                and the WHO, more than 6 000 work place fatalities are
427   II,     7.  3.  4    |             They range from 0.3 per 100 000 inhabitants in the United
428   II,     7.  3.  4    |               in the EU27 is 22 per 100,000 residents and is more than
429   II,     7.  3.  4    |                every year more than 100 000 EU citizens die from home
430   II,     7.  3.  5    |                 of all cases, almost 61 000 people a yearsee Figure
431   II,     7.  3.  5    |               vary from about 2 per 100 000 people in Cyprus to 35 per
432   II,     7.  3.  5    |                 in Cyprus to 35 per 100 000 in Lithuania (Figure 7.15.
433   II,     7.  4.  1    |                 Every year more than 20 000 people in this age group
434   II,     7.  4.  2    |            Every year approximately 105 000 people aged 65 or older
435   II,     7.  4.  3    |                of injury. Each year, 45 000 people are killed on EU
436   II,     7.  4.  4    |               EU-region counts some 700 000 sport clubs.~ ~However,
437   II,     7.  7        |        Standardised Death Rate (per 100 000 inhabitants), Suicide and
438   II,     7.  7        |        Standardised Death Rate (per 100 000 inhabitants), Homicide,
439   II,     8.  2.  1    |                with sample sizes of N=1,000, to population based census
440   II,     9            |           Region before age 65, per 100.000 population.~ ~ ~ ~Source:
441   II,     9.  1        |               Of these, an estimated 25 000 are stillborn and an additional
442   II,     9.  1        |          stillborn and an additional 25 000 die within their first year (
443   II,     9.  1        |             survivors, an additional 40 000 (approximately 8 per 1 000
444   II,     9.  1        |              000 (approximately 8 per 1 000 survivors) experience severe
445   II,     9.  1        |       frequently - only 5 to 15 per 100 000 live births – but are associated
446   II,     9.  1.  1    |           ranged from 6.4 to 22.1 per 1 000 total births in the current
447   II,     9.  1.  1    |            ranged from 1.6 to 9.5 per 1 000 births. Neonatal mortality
448   II,     9.  1.  1    |                 rates are about 2 per 1 000 births in Sweden, Luxembourg,
449   II,     9.  1.  1    |               Finland, but over 5 per 1 000 in Bulgaria, Latvia and
450   II,     9.  1.  1    |         mortality in 2004 was 2.7 per 1 000 births. This median rate
451   II,     9.  1.  1    |             rate was much higher (4.4/1 000) among countries that joined
452   II,     9.  1.  1    |              three times greater (8.5/1 000) among countries that acceded
453   II,     9.  1.  1    |             foetal mortality (3.9 per 1 000 births) between the original
454   II,     9.  1.  1    |                 was higher at 6.9 per 1 000 births.~ ~F ~ ~Infant mortality
455   II,     9.  1.  1    |           occurring in 1.5 to 2.5 per 1 000 live births. Cerebral Palsy
456   II,     9.  1.  1    |                 countries, is 2.0 per 1 000 live births. As shown in
457   II,     9.  1.  1    |              Cerebral palsy rates per 1 000 live births in selected
458   II,     9.  1.  1    |                is, on average, 94 per 1 000 live births during the period
459   II,     9.  1.  1    |               per country from 26 per 1 000 live births (Lithuania)
460   II,     9.  1.  1    |              Lithuania) up to 164 per 1 000 live births (Ireland). This
461   II,     9.  1.  2    |                 anomalies of 23.8 per 1 000 births for 2000-2004 (Table
462   II,     9.  1.  2    |                prevalence is 19.9 per 1 000 births.~ ~Table 9.1.2.1.
463   II,     9.  1.  2    |                 1.2.1. Prevalence per 1 000 births of EUROCAT congenital
464   II,     9.  1.  2    |      chromosomal anomalies is 3.4 per 1 000 births. In the data shown
465   II,     9.  1.  2    |           common subgroup, at 6.4 per 1 000 births, followed by limb
466   II,     9.  1.  2    |                 limb defects (3.6 per 1 000), urinary system (2.8 per
467   II,     9.  1.  2    |               urinary system (2.8 per 1 000) and nervous system defects (
468   II,     9.  1.  2    |               system defects (2.0 per 1 000). EUROCAT updates each year
469   II,     9.  1.  2    |              prevalence above 0.1 per 1 000 births are shown in Table
470   II,     9.  1.  2    |             live birth prevalence per 1 000 births of All Anomalies
471   II,     9.  1.  2    |        congenital anomaly is 0.43 per 1 000 births, and deaths in the
472   II,     9.  1.  2    |               the first week 0.55 per 1 000 births, giving a total perinatal
473   II,     9.  1.  2    |        congenital anomaly of 0.99 per 1 000 births (Table 9.1.2.2).
474   II,     9.  1.  2    |            recorded in Italy (0.2 per 1 000) but there is a known problem
475   II,     9.  1.  2    |          recorded in Ireland (2.4 per 1 000) and Malta (2.3 per 1 000).
476   II,     9.  1.  2    |               000) and Malta (2.3 per 1 000). These are both countries
477   II,     9.  1.  2    |               Perinatal Mortality per 1 000 births, by country, 2000-
478   II,     9.  1.  2    |                  to 11.4 (France) per 1 000 births. Differing prenatal
479   II,     9.  1.  2    |               France (5.6 and 5.8 per 1 000 births respectively). Comparison
480   II,     9.  1.  2    |              heart disease is 6.1 per 1 000 births (Table 9.1.2.1),
481   II,     9.  1.  2    |                prevalence of 8-10 per 1 000. The reported prevalence
482   II,     9.  1.  2    |             across Europe, to 2.2 per 1 000 births. Geographical variation
483   II,     9.  1.  2    |                 and TOPFA) of 3.4 per 1 000.~ ~Figure 9.1.2.2. Trends
484   II,     9.  1.  2    |             live birth prevalence per 1 000 births of Down Syndrome,
485   II,     9.  1.  2    |            Figure 9.1.2.2) to 1.0 per 1 000 births as the increase in
486   II,     9.  1.  2    |                  ranging from 0.4 per 1 000 to 2.0 per 1 000 (the high
487   II,     9.  1.  2    |                4 per 1 000 to 2.0 per 1 000 (the high rates being in
488   II,     9.  1.  2    |             live birth prevalence per 1 000 births of Neural Tube Defects
489   II,     9.  1.  2    |             live birth prevalence per 1 000 births of Neural Tube Defects,
490   II,     9.  1.  2    |        prevalence rates, from 0.1 per 1 000 in France and Spain to 1.
491   II,     9.  1.  2    |           France and Spain to 1.0 per 1 000 in Poland (Table 9.1.2.4).~ ~
492   II,     9.  1.  2    |            cleft lip occur in 1.3 per 1 000 births in Europe (Table
493   II,     9.  1.  2    |               between 1.3 and 1.6 per 1 000 for 2000-2004 (EUROCAT,
494   II,     9.  1.  2    |                while rates of 0.6 per 1 000 or below were recorded in
495   II,     9.  1.  2    |                 prevalence of 0.2 per 1 000 births in 2000-2004 (Table
496   II,     9.  1.  2    |               of a minimum of 1.3 per 1 000 births (Table 9.1.2.1).
497   II,     9.  1.  2    |        prevalence rates up to 2.5 per 1 000 in the period 2000-2004,
498   II,     9.  1.  2    |        prevalenceSicily at 3.0 per 1 000, and Malta at 4.2 per 1
499   II,     9.  1.  2    |                  and Malta at 4.2 per 1 000. It is difficult to produce
500   II,     9.  1.  2    |           prevalence less than 5 per 10 000 in the EU), depending on